These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
540 related articles for article (PubMed ID: 32873927)
1. Management of brain metastases according to molecular subtypes. Soffietti R; Ahluwalia M; Lin N; Rudà R Nat Rev Neurol; 2020 Oct; 16(10):557-574. PubMed ID: 32873927 [TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
3. Current Treatment Options for Breast Cancer Brain Metastases. Raghunath A; Desai K; Ahluwalia MS Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009 [TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225 [TBL] [Abstract][Full Text] [Related]
5. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101 [TBL] [Abstract][Full Text] [Related]
7. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957 [TBL] [Abstract][Full Text] [Related]
8. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598 [TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping of brain metastases and implications for therapy. Renfrow JJ; Lesser GJ Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440 [TBL] [Abstract][Full Text] [Related]
10. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic options for brain metastases]. Preusser M; Winkler F Nervenarzt; 2015 Jun; 86(6):716-8. PubMed ID: 25989738 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress. Liu L; Chen W; Zhang R; Wang Y; Liu P; Lian X; Zhang F; Wang Y; Ma W Cancer Biol Med; 2020 Nov; 17(4):910-922. PubMed ID: 33299643 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965 [TBL] [Abstract][Full Text] [Related]
15. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046 [TBL] [Abstract][Full Text] [Related]
17. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077 [TBL] [Abstract][Full Text] [Related]
18. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. Yomo S; Hayashi M; Cho N J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546 [TBL] [Abstract][Full Text] [Related]
19. Targeted and immunotherapeutic approaches in brain metastases. Ahluwalia MS; Winkler F Am Soc Clin Oncol Educ Book; 2015; ():67-74. PubMed ID: 25993144 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]